Patrick Mauro Investment Advisor INC. Has $5.06 Million Stock Position in CVS Health Co. (NYSE:CVS)

Patrick Mauro Investment Advisor INC. lowered its position in shares of CVS Health Co. (NYSE:CVS - Free Report) by 9.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 112,698 shares of the pharmacy operator's stock after selling 12,316 shares during the period. CVS Health makes up about 2.9% of Patrick Mauro Investment Advisor INC.'s investment portfolio, making the stock its 15th largest position. Patrick Mauro Investment Advisor INC.'s holdings in CVS Health were worth $5,059,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Stonebridge Financial Group LLC acquired a new position in shares of CVS Health during the fourth quarter valued at $28,000. Hopwood Financial Services Inc. bought a new stake in CVS Health in the fourth quarter worth about $29,000. McIlrath & Eck LLC raised its holdings in CVS Health by 32.6% during the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after buying an additional 174 shares during the period. Financial Perspectives Inc increased its holdings in shares of CVS Health by 137.5% in the 4th quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock valued at $36,000 after purchasing an additional 466 shares during the period. Finally, MidAtlantic Capital Management Inc. grew its stake in shares of CVS Health by 112.1% in the 4th quarter. MidAtlantic Capital Management Inc. now owns 827 shares of the pharmacy operator's stock valued at $37,000 after buying an additional 437 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on CVS shares. Edward Jones raised CVS Health from a "hold" rating to a "buy" rating in a research report on Thursday, January 30th. Barclays raised their price target on CVS Health from $73.00 to $82.00 and gave the company an "overweight" rating in a report on Friday, May 2nd. Mizuho raised their price target on CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Wolfe Research boosted their price target on CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Finally, Leerink Partnrs upgraded CVS Health from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 12th. Three research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and a consensus price target of $74.94.

CVS Health Price Performance

Shares of CVS Health stock traded up $0.56 on Tuesday, hitting $61.39. 2,470,347 shares of the company were exchanged, compared to its average volume of 11,294,748. The stock has a market capitalization of $77.66 billion, a price-to-earnings ratio of 16.77, a price-to-earnings-growth ratio of 0.98 and a beta of 0.60. The company has a 50-day moving average price of $66.01 and a 200 day moving average price of $59.45. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $72.51. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The business had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. During the same quarter in the prior year, the company earned $1.31 earnings per share. The company's revenue was up 7.0% on a year-over-year basis. As a group, sell-side analysts predict that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 4.33%. CVS Health's dividend payout ratio (DPR) is currently 63.48%.

Insider Buying and Selling at CVS Health

In other CVS Health news, SVP James David Clark sold 7,513 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now directly owns 8,394 shares of the company's stock, valued at $556,941.90. The trade was a 47.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.22% of the stock is owned by company insiders.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.